CEACAM5 and non-small cell lung carcinoma: Herein, the patients given osimertinib had significantly lower levels of CEA and VEGF versus those given pemetrexed plus cisplatin, indicating that osimertinib can effectively downregulate serum CEA and VEGF levels in patients with non-small cell lung cancer, which thus mirrors its inhibition of tumor cell growth or metastasis.